WHO ICTRP trial
Safety of continued use of oral docetaxel in patients with advanced solid types…
EUCTR2017-000347-41-NL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-000347-41-NL |
|---|---|
| Public title | Safety of continued use of oral docetaxel in patients with advanced solid types of cancer |
| Scientific title | Safety of extended use of the weekly oral docetaxel formulation ModraDoc006/r in patients with advanced solid tumours - Extended use of ModraDoc006/r |
| Primary sponsor | Modra Pharmaceuticals BV |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Advanced solid malignancies MedDRA version: 19.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified… |
| Interventions | Product Name: ModraDoc006 Pharmaceutical Form: Tablet INN or Proposed INN: DOCETAXEL CAS Number: 114977-28-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: Ritonavir Product Name… |
| Registration date | Feb 22, 2017 |
| Target size | 45 |
| Secondary IDs | N17DEX |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: